TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35668532
Drug: 3-week multimodal,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-week multimodal, individualized prehabilitation program including exercise therapy, nutritional intervention, mobility or balance training, and psychosocial interventions and medical assessment, supervised 5 times/week for 3 weeks.
Study: 32846841
Drug: Bidirectional barbed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bidirectional barbed suture (Stratafix1-0 for joint capsule, Stratafix2-0 for subcutaneous, Stratafix3-0 for intracutaneous)
Study: 32846841
Drug: Traditional absorbable
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional absorbable suture (Ethicon VICRYL* Plus 1-0 for joint capsule, Ethicon VICRYL* Plus 2-0 for subcutaneous, staples for skin)
Study: 34664106
Drug: CAF-6 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF-6 (6 mg/kg caffeine)
Study: 34664106
Drug: CAF-3 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF-3 (3 mg/kg caffeine)
Study: 32589244
Drug: Analgesic treatment
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic treatment only (Group A)
Study: 32589244
Drug: Chest physiotherapy
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest physiotherapy and analgesic treatment (Group B)
Study: 33068791
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) with a prescribed dose of 35 Gy in five fractions
Study: 32474728
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (both doses)
Study: 33413311
Drug: IV iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV iron therapy (4 weeks before surgery)
Study: 33413311
Drug: Autologous whole
Normalized name: Autologous whole blood product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous whole blood therapy (2 units collected 4 and 2 weeks before surgery)
Study: 33413311
Drug: IV iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV iron therapy
Study: 33413311
Drug: Autologous whole
Normalized name: Autologous whole blood product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous whole blood therapy
Study: 36000037
Drug: High-dose intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intranasal desmopressin (40 μg)
Study: 36000037
Drug: Low-dose intranasal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intranasal desmopressin (20 μg)
Study: 33142037
Drug: Sinbaglustat (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinbaglustat (10 to 2000 mg single doses; 30 to 1000 mg twice daily for 7 days)
Study: 35723814
Drug: Ruyi Zhenbao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruyi Zhenbao Pills (RZPs) for 4 weeks
Study: 35867804
Drug: istaroxime 1.0‐1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: istaroxime 1.0‐1.5 μg/kg/min
Study: 32898271
Drug: Recombinant HA
Normalized name: Recombinant haemagglutinin protein-strain A (H3N2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant HA vaccine (rHA)
Study: 32898271
Drug: Egg-derived inactivated
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg-derived inactivated influenza vaccine (IIV)
Study: 32898271
Drug: Cell-derived inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell-derived inactivated influenza vaccine (IIV)
Study: 33991711
Drug: Anti-VEGF injections
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-VEGF injections (as-needed regimen)
Study: 34358954
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 300 mg glycerol monolaurate/kg
Study: 34840945
Drug: e-Yoga intervention
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: e-Yoga intervention administered via e-Yoga modalities
Study: 36320174
Drug: Betahistine 24
Normalized name: betahistine 24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 24 mg every 12 h for 90 days
Study: 36320174
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets every 12 h for 90 days
Study: 35717595
Drug: ECHO (carer
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECHO (carer skills intervention) added to treatment as usual (TAU)
Study: 33597136
Drug: Increased physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased physical activity (daily walking)
Study: 32900508
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (15 mg isobaric bupivacaine 0.5% with 0.5 ml normal saline 0.9%)
Study: 36694242
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (weekly pick-up with monthly check-ups)
Study: 33638741
Drug: Screw augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screw augmentation with bone cement
Study: 33638741
Drug: No screw
Approvals — FDA: no, EMA: no, PMDA: no
Description: No screw augmentation
Study: 34495285
Drug: Online 1-day
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online 1-day cognitive behavioral therapy (CBT)-based workshop plus usual care (n = 202)
Study: 33508495
Drug: COC users
Approvals — FDA: no, EMA: no, PMDA: no
Description: COC users (Microgynon®) during day 15-16 of pill consumption (PC2)
Study: 33508495
Drug: COC users
Approvals — FDA: no, EMA: no, PMDA: no
Description: COC users (Microgynon®) during day 2-3 of pill consumption (PC1)
Study: 32043148
Drug: Supervised rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised rehabilitation intervention (physical therapy and occupational therapy-based interventions)
Study: 32410849
Drug: Pioglitazone Metformin
Normalized name: metformin / pioglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone Metformin complex (PM)
Study: 32801009
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in triglycerides by 1 mmol/L (89 mg/dL)
Study: 32459348
Drug: e-coach-guided, web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: e-coach-guided, web-based self-help intervention based on cognitive behavioral therapy
Study: 34726293
Drug: Ethosuximide 500
Normalized name: Ethosuximide
DrugBank: Ethosuximide (DB00593)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethosuximide 500 mg t.i.d along with mebeverine 135 mg t.i.d
Study: 34726293
Drug: Mebeverine 135
Normalized name: mebeverine 135 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebeverine 135 mg t.i.d
Study: 33041091
Drug: ω‐3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 PUFA therapy (2 g daily for 3 months)
Study: 32791681
Drug: Tonifying Kidney
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonifying Kidney and Invigorating Brain acupuncture plus standardized physical rehabilitation treatment
Study: 32791681
Drug: Standardized physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized physical rehabilitation treatment
Study: 32813051
Drug: COVID Impact
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID Impact Survey administered during the pandemic
Study: 34080498
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) paracetamol
Study: 34080498
Drug: Modified-release (MR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release (MR) paracetamol
Study: 34080498
Drug: Both IR
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both IR and MR paracetamol
Study: 35482532
Drug: Avacopan 30
Normalized name: Avacopan
DrugBank: Avacopan (DB15011)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avacopan 30 mg twice daily for 52 weeks
Study: 36087921
Drug: Virtual simulation-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual simulation-based training program for etonogestrel subdermal contraceptive implant insertion and removal
Study: 32056721
Drug: Low-dose indacaterol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose indacaterol acetate/mometasone furoate 150/80 μg once daily
Study: 32056721
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 200 μg once daily
Study: 34600129
Drug: Locoregional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional therapy plus adoptive transfer of allogeneic γδ T cells (HCC, Group B; ICC, Group D)
Study: 34600129
Drug: Locoregional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional therapy (HCC, Group A; ICC, Group C)
Study: 34600129
Drug: Locoregional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional therapy plus adoptive transfer of allogeneic γδ T cells (HCC, Group B)
Study: 34600129
Drug: Locoregional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional therapy (HCC, Group A)
Study: 34600129
Drug: Locoregional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional therapy plus adoptive transfer of allogeneic γδ T cells (ICC, Group D)
Study: 34600129
Drug: Locoregional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional therapy (ICC, Group C)
Study: 32945567
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy and therapeutic alliance feedback
Study: 36256926
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE, 0.625 mg/d)
Study: 36256926
Drug: CEE +
Normalized name: Conjugated Estrogen Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE + medroxyprogesterone acetate (MPA; 2.5 mg/d)
Study: 36454738
Drug: Talazoparib vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib vs Standard therapy
Study: 33853099
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy for 30 minutes
Study: 33565303
Drug: Educational programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational programme and actual insulin injection demonstration (physician-led sample insulin injection using an insulin pen)
Study: 32506857
Drug: Jinying capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinying capsules and oral levofloxacin plus oral metronidazole for first 7 days, followed by Jinying capsules with levofloxacin placebo and metronidazole placebo for another 7 days, and then Jinying capsules only for the remaining 14 days.
Study: 32506857
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received oral levofloxacin and metronidazole with Jinying capsule placebo for the first 14 days, followed by Jinying capsule placebo only for the remaining 14 days.
Study: 32506857
Drug: Jinying capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinying capsules (experimental group) vs. Jinying capsule placebo (control group) in TCM symptom pattern scores before and after treatment.
Study: 36299540
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy with Adaptive Virtual Reality Exposure (CBT-ExpVR)
Study: 36299540
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy with In Vivo Exposure (CBT-Exp)
Study: 33655943
Drug: Conventional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatments for neglect symptoms (n=12)
Study: 33079935
Drug: Nutrient bar
Normalized name: Votrient
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nutrient bar supplementation (2 bars daily for 2 months)
Study: 34052212
Drug: IV continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV continuous diuretic therapy
Study: 34052212
Drug: IV intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV intermittent bolus diuretic therapy
Study: 34052212
Drug: Oral diuretic
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diuretic therapy
Study: 34518101
Drug: Remifentanil group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil group (group R) with remifentanil infusion
Study: 35550819
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (Warfarin and antiplatelets)
Study: 35550819
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (in patients with MS)
Study: 34257570
Drug: Simultaneous Integrated
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous Integrated Boost (SIB) delivered using RapidArc technique at doses of 2.4 Gy per fraction during pelvic irradiation with 50.4/1.8 Gy, total dose of 67.2 Gy for limited volume disease; parametric boost therapy added for advanced disease to a total dose of 79.2 Gy.
Study: 34257570
Drug: Simultaneous cisplatin‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous cisplatin‐based chemotherapy for 5 cycles with a dosage of 40 mg/m2.
Study: 32424028
Drug: Antimalarial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimalarial treatment
Study: 35084726
Drug: Nebulized heliox
Normalized name: Helixate
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized heliox (helium/oxygen‐70: 30) plus albuterol (10 mL/min for 20 minutes, three times)
Study: 35084726
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (albuterol in combination with oxygen)
Study: 34693931
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ARV)
Study: 34412512
Drug: Endovascular thrombectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular thrombectomy with intravenous thrombolysis
Study: 34303029
Drug: SRP+aPDT (scaling
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP+aPDT (scaling and root planing followed by 3 consecutive applications of antimicrobial photodynamic therapy)
Study: 32251176
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg)
Study: 35403286
Drug: Probiotic and
Normalized name: Florastor Advanced Probiotic And Digestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic and Peanut Oral Immunotherapy (PPOIT)
Study: 35368052
Drug: SLN360 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLN360 30 mg
Study: 35368052
Drug: SLN360 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLN360 100 mg
Study: 35368052
Drug: SLN360 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLN360 300 mg
Study: 35368052
Drug: SLN360 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLN360 600 mg
Study: 33758008
Drug: P2Y12 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P2Y12 inhibitor monotherapy after 3-month DAPT
Study: 36251618
Drug: Levoketoconazole (150-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levoketoconazole (150-600 mg BID)
Study: 32488909
Drug: Bevacizumab in
Normalized name: bevacizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab in combination with neoadjuvant chemotherapy (FEC100 and taxanes)
Study: 36419615
Drug: 4D dietary
Normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4D dietary supplement containing 150 mg of caffeine
Study: 32128957
Drug: Efpeglenatide 8
Normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efpeglenatide 8 mg once monthly
Study: 32128957
Drug: Efpeglenatide 12
Normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efpeglenatide 12 mg once monthly
Study: 32128957
Drug: Efpeglenatide 16
Normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efpeglenatide 16 mg once monthly
Study: 32886918
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (external ventricular drain with antibiotics)
Study: 32991606
Drug: Pelubiprofen CR
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pelubiprofen CR 90 mg
Study: 32991606
Drug: Aceclofenac 200
Normalized name: Aceclofenac 200 mg prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceclofenac 200 mg
Study: 32115753
Drug: RAI oral/dental
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAI oral/dental items assessment
Study: 35961692
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel (AC)
Study: 35961692
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and ticagrelor (AT)
Study: 35961692
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and prasugrel (AP)
Study: 34479632
Drug: Emotion-focused mindfulness
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emotion-focused mindfulness therapy (EFMT) delivered via telehealth (Zoom)
Study: 34479632
Drug: Wait list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait list control (no treatment)
Study: 35711820
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg intramuscular nandrolone
Study: 34613339
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment (fluoropyrimidine-based chemotherapy with bevacizumab)
Study: 34613339
Drug: Primary tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary tumor resection (PTR) followed by systemic treatment (fluoropyrimidine-based chemotherapy with bevacizumab)
Study: 36188617
Drug: Tailin formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailin formulation (TLF) + Continuous low-dose antibiotic therapy (CLAT)
Study: 36188617
Drug: Continuous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous low-dose antibiotic therapy (CLAT)
Study: 32936838
Drug: Human monoclonal
Normalized name: ANTI-A33 FULLY-HUMAN MONOCLONAL ANTIBODY
DrugBank: KRN-330 (DB19075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human monoclonal antibodies (MAbs) derived from genotype B5 virus-infected individuals
Study: 32936838
Drug: Neutralizing antibodies
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing antibodies targeting VP1 S241, VP3 E81, and VP2 D84 on genotype C1 viral capsid
Study: 32936838
Drug: Neutralizing antibodies
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing antibodies in hSCARB2-transgenic mice model
Study: 35242191
Drug: L‐PRF over
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐PRF over ATBG around immediately inserted implants (test group)
Study: 35242191
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without L‐PRF)
Study: 33568038
Drug: Kinesitherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesitherapy combined with daily administration of Fortigel®, Vitamin C, sodium hyaluronate, manganese and copper (Group B)
Study: 34101206
Drug: Topical silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical silymarin cream 1.4% (3-month treatment)
Study: 32778175
Drug: D-ribose supplementation
Normalized name: beta-D-ribose
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-ribose supplementation (15g in 200ml solution)
Study: 34254731
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi intervention (1-hour class twice weekly for 16 weeks)
Study: 33432459
Drug: Salacia chinensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salacia chinensis (SC; 500 mg)
Study: 33040778
Drug: Dengzhanshengmai capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengzhanshengmai capsules combined with butylphthalide softgels
Study: 33040778
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group A (butylphthalide soft capsules)
Study: 33040778
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group B (Dengzhanshengmai capsules)
Study: 35435091
Drug: Plasma Exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma Exchange (PE) treatment
Study: 35900386
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (TXA) 500 mg/5 ml
Study: 35900386
Drug: Moffett’s solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moffett’s solution (control)
Study: 35217236
Drug: Sitagliptin/metformin (sitaformin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin/metformin (sitaformin)
Study: 33091433
Drug: SYN023 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYN023 (0.3 mg/kg) alone
Study: 33091433
Drug: SYN023 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYN023 (0.3 mg/kg) in combination with rabies vaccine
Study: 38834432
Drug: SYN023 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYN023 (0.3 mg/kg)
Study: 34419285
Drug: Tivozanib 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivozanib 1.5 mg orally once daily for 21 days in a 28-day cycle